BACKGROUND AND MISSION
Medicines for Malaria Venture (MMV) is a non-profit public-private partnership, which was established as a foundation in Switzerland in 1999. MMV is a leading product development partnership in the field of antimalarial drug research and development. As such it is dedicated to reducing the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. MMV strives towards a world in which innovative medicines will cure and protect the vulnerable populations at risk of malaria, to ultimately help eradicate the disease.

AREAS OF INTEREST
- Malaria prevention and treatment
- Drug development and registration
- Access to antimalarials

HEALTH-RELATED ACTIVITIES
MMV is currently managing the largest ever portfolio of over 65 antimalarial drug development projects in collaboration with over 400 pharmaceutical, academic and endemic-country partners in more than 55 countries. Till date, MMV and its partners have brought forward 11 new antimalarials estimated to have saved over 2 million lives. The majority of the new drugs under development target vulnerable populations, such as children, infants and pregnant women at risk of malaria, as well as people suffering from relapsing or drug-resistant malaria.

GOVERNANCE AND STAFF
The chairperson of the MMV board of directors is Mr Per Wold-Olsen and the CEO of the organisation is Dr David Reddy. The headquarters in Geneva employ over 65 permanent staff members.

FUNDING SOURCES AND BUDGET
MMV is funded by pledged donations. Since 1999, MMV has received funding from 28 public, private and philanthropic donors including the Bill and Melinda Gates Foundation and the UK Department for International Development.

PUBLICATIONS
For all MMV publications, see: http://www.mmv.org/newsroom/publications

Last update: 05.11.2019